Remibrutinib MS Trial Success
Novartis reports positive Phase 3 results for remibrutinib in relapsing multiple sclerosis trials.
Anonymous
Key Points
1
Remibrutinib's REMODEL-1 and REMODEL-2 trials enrolled over 2,000 patients worldwide, used teriflunomide as the active comparator, and demonstrated a significantly lower annualized relapse rate and fewer new MRI lesions, with a preplanned combined analysis indicating a clinically meaningful delay in 3-month and 6-month confirmed disability progression.
2
Novartis plans to file regulatory applications for relapsing MS worldwide, with analysts forecasting peak annual sales for remibrutinib ranging from about $3 billion up to $9 billion.
3
Remibrutinib already holds FDA approval for chronic spontaneous urticaria (marketed as Rhapsido) with approvals in the US, EU, and Japan, and recent developments anchor its potential for multi‑indication growth ( CSU approval dated September 2025 per the reporting).
4
Investors reacted positively to the MS trial news, with Novartis shares trading higher on the remibrutinib trial results.
Novartis announced positive Phase 3 results for remibrutinib, its oral MS drug, in two large trials called REMODEL-1 and REMODEL-2. Yahoo Finance reports the company's stock jumped 6% to $161.10 after the oral BTK inhibitor beat its main goals, reducing relapses and brain lesions better than the existing drug Aubagio. Novartis now plans to seek regulatory approval for remibrutinib in relapsing multiple sclerosis worldwide.
Two Trials Show Remibrutinib Cuts Relapses Sharply
The REMODEL-1 and REMODEL-2 trials enrolled over 2,000 patients globally and tested remibrutinib against teriflunomide, an existing MS drug. Yahoo Finance reports remibrutinib delivered significantly fewer annual relapses and fewer new MRI brain lesions than the comparator. The combined analysis also showed a clinically meaningful delay in disability progression at both three and six months.
Safety Profile Supports Long-Term Use Potential
Novartis emphasized that remibrutinib showed a consistent safety profile with no liver safety concerns during the trials. This clean safety record matters because patients may take MS drugs for years or decades. The company's focus on safety bolsters confidence that remibrutinib could become a long-term treatment option for people with relapsing MS.
Remibrutinib Already Approved for Skin Condition
Remibrutinib already holds FDA approval for chronic spontaneous urticaria, a severe skin itch condition, under the brand name Rhapsido. The drug won approval in the US, Europe, and Japan as early as September 2025. Success in MS could unlock much larger sales, with analysts forecasting peak annual revenue between $3 billion and $9 billion across all uses.
Regulatory Filing Expected as Market Readies for Details
Novartis plans to file for MS approval in all major markets. The company will present more data at MSToronto2026, a major conference for neurologists. Investors cheered the trial win, viewing remibrutinib as a potential blockbuster drug that could drive significant future growth for Novartis.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
68
Reach
80
A
AnonymousAuthor
